go to home page go to home page
Euclid SR Partners
Euclid SR Partners

08/03/2010 FatWire Reports Strong H1 2010 Results Driven by 78 Percent License Revenue Growth
06/23/2010 AstraZeneca and Targacept Initiate Phase 3 Clinical Development of TC-5214 as an Adjunct Treatment for Major Depressive Disorder
06/08/2010 Positive Results From Phase 2 Study of Qnexa in Obstructive Sleep Apnea Presented at Sleep Meeting
03/01/2010 Fluidigm Selected by MIT's Technology Review Magazine as one of the 50 Most Innovative Companies in the World
11/18/2009 VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect Profile
11/16/2009 Targacept Added to NASDAQ Biotechnology Index
11/09/2009 FatWire Named An Innovative Information Access Company To Watch By Leading Market Research Firm
10/29/2009 Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
10/15/2009 Targacept Presents Data from Highly Successful Phase 2b Trial of TC-5214 as Augmentation Treatment for Major Depressive Disorder
10/07/2009 Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph. D., Awarded the 2009 Nobel Prize in Chemistry
09/09/2009 VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
07/15/2009 Targacept's TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder




[ Experience | Focus | Involvement | Investments | Submit | Contacts | Press | Home ]